RT Journal Article
SR Electronic
T1 A Rapid and Low-Cost protocol for the detection of B.1.1.7 lineage of SARS-CoV-2 by using SYBR Green-Based RT-qPCR
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.27.21250048
DO 10.1101/2021.01.27.21250048
A1 Sater, Fadi Abdel
A1 Younes, Mahmoud
A1 Nassar, Hassan
A1 Nguewa, Paul
A1 Hamze, Kassem
YR 2021
UL http://medrxiv.org/content/early/2021/01/29/2021.01.27.21250048.abstract
AB Background The new SARS-CoV-2 variant VUI (202012/01), identified recently in the United Kingdom (UK), exhibits a higher transmissibility rate compared to other variants, and a reproductive number 0.4 higher. In the UK, scientists were able to identify the increase of this new variant through the rise of false negative results for the spike (S) target using a three-target RT-PCR assay (TaqPath kit).Methods To control and study the current coronavirus pandemic, it is important to develop a rapid and low-cost molecular test to identify the aforementioned variant. In this work, we designed primer sets specific to SARS-CoV-2 variant VUI (202012/01) to be used by SYBR Green-based RT-PCR. These primers were specifically designed to confirm the deletion mutations Δ69/Δ70 in the spike and the Δ106/Δ107/Δ108 in the NSP6 gene. We studied 20 samples from positive patients, 16 samples displayed an S-negative profile (negative for S target and positive for N and ORF1ab targets) and four samples with S, N and ORF1ab positive profile.Results Our results emphasized that all S-negative samples harbored the mutations Δ69/Δ70 and Δ106/Δ107/Δ108. This protocol could be used as a second test to confirm the diagnosis in patients who were already positive to COVID-19 but showed false negative results for S-gene.Conclusions This technique may allow to identify patients carrying the VUI (202012/01) variant or a closely related variant, in case of shortage in sequencing.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialIRB AL RASOUL ALAAZAM Hospital, Beirut, LebanonFunding StatementThis work was supported by the Lebanese University and Fundacion La Caixa (LCF/PR/PR13/11080005), Fundacion Caja Navarra, Fundacion Roviralta, Ubesol, Inversiones Garcilaso de la Vega, COST Actions CA18217 and CA18218, and EU Project uncover (Grant/Award Number: 101016216).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB AL RASOUL ALAAZAM Hospital, Beirut, lebanon.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are present in the manuscript